Opioid Activation of Toll-Like Receptor 4 Contributes to Drug Reinforcement
Open Access
- 15 August 2012
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 32 (33), 11187-11200
- https://doi.org/10.1523/jneurosci.0684-12.2012
Abstract
Opioid action was thought to exert reinforcing effects solely via the initial agonism of opioid receptors. Here, we present evidence for an additional novel contributor to opioid reward: the innate immune pattern-recognition receptor, toll-like receptor 4 (TLR4), and its MyD88-dependent signaling. Blockade of TLR4/MD2 by administration of the nonopioid, unnatural isomer of naloxone, (+)-naloxone (rats), or two independent genetic knock-outs of MyD88-TLR4-dependent signaling (mice), suppressed opioid-induced conditioned place preference. (+)-Naloxone also reduced opioid (remifentanil) self-administration (rats), another commonly used behavioral measure of drug reward. Moreover, pharmacological blockade of morphine-TLR4/MD2 activity potently reduced morphine-induced elevations of extracellular dopamine in rat nucleus accumbens, a region critical for opioid reinforcement. Importantly, opioid-TLR4 actions are not a unidirectional influence on opioid pharmacodynamics, sinceTLR4−/−mice had reduced oxycodone-induced p38 and JNK phosphorylation, while displaying potentiated analgesia. Similar to our recent reports of morphine-TLR4/MD2 binding, here we provide a combination ofin silicoand biophysical data to support (+)-naloxone and remifentanil binding to TLR4/MD2. Collectively, these data indicate that the actions of opioids at classical opioid receptors, together with their newly identified TLR4/MD2 actions, affect the mesolimbic dopamine system that amplifies opioid-induced elevations in extracellular dopamine levels, therefore possibly explaining altered opioid reward behaviors. Thus, the discovery of TLR4/MD2 recognition of opioids as foreign xenobiotic substances adds to the existing hypothesized neuronal reinforcement mechanisms, identifies a new drug target in TLR4/MD2 for the treatment of addictions, and provides further evidence supporting a role for central proinflammatory immune signaling in drug reward.Keywords
This publication has 64 references indexed in Scilit:
- Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: Comparison of different mouse strainsBrain, Behavior, and Immunity, 2011
- Minocycline reduces ethanol drinkingBrain, Behavior, and Immunity, 2011
- Minocycline attenuates subjective rewarding effects of dextroamphetamine in humansPsychopharmacology, 2010
- Evidence that opioids may have toll-like receptor 4 and MD-2 effectsBrain, Behavior, and Immunity, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine releaseBrain, Behavior, and Immunity, 2009
- Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast)Brain, Behavior, and Immunity, 2009
- Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesiaBrain, Behavior, and Immunity, 2008
- Proinflammatory cytokines oppose opioid-induced acute and chronic analgesiaBrain, Behavior, and Immunity, 2008
- Dopamine reward circuitry: Two projection systems from the ventral midbrain to the nucleus accumbens–olfactory tubercle complexBrain Research Reviews, 2007